NASDAQ
9.88USD
+0.55 (+5.89%)
We have scored 4 news catalysts on Sagimet Biosciences Inc. (SGMT) over the past 12 months. The biggest single-day move next to one of them came Aug 5, 2026, when SGMT closed +8.1%: “Sagimet: A Look Ahead To Earnings And A Catalyst-Heavy H2 2026”. Coverage across the window leans positive (average ticker sentiment +0.77). Most of the impact sits in short squeeze potential and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
321.9M
P/E
—
EPS
—
Beta
3.49
52W range
4.5-11.45
Day range
9.46–10.90
Open
10.76
Prev close
9.33
Volume
5.5M
Avg volume
1.2M
Dividend
0.00
IPO
2023-07-14
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Sagimet Biosciences Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for SGMT: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
